Stoneridge Investment Partners LLC Has $2.39 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Stoneridge Investment Partners LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 106.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 16,555 shares of the company’s stock after acquiring an additional 8,517 shares during the period. Stoneridge Investment Partners LLC’s holdings in Johnson & Johnson were worth $2,394,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Powers Advisory Group LLC grew its stake in Johnson & Johnson by 0.6% during the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock worth $1,538,000 after buying an additional 61 shares during the last quarter. Knuff & Co LLC boosted its holdings in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after acquiring an additional 64 shares in the last quarter. Vertex Planning Partners LLC increased its holdings in Johnson & Johnson by 1.3% during the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after purchasing an additional 65 shares in the last quarter. Freedom Day Solutions LLC raised its position in Johnson & Johnson by 1.1% in the 3rd quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company’s stock valued at $1,016,000 after purchasing an additional 66 shares during the last quarter. Finally, Traphagen Investment Advisors LLC boosted its stake in Johnson & Johnson by 0.6% in the third quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company’s stock worth $1,699,000 after purchasing an additional 67 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Wells Fargo & Company lowered their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Morgan Stanley decreased their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Finally, Barclays boosted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $170.67.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.3 %

Shares of NYSE:JNJ opened at $156.18 on Wednesday. The company has a 50 day moving average price of $147.40 and a two-hundred day moving average price of $156.04. The company has a market capitalization of $376.02 billion, a PE ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter last year, the business posted $2.29 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.